Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V2FZ
|
|||
| Former ID |
DIB011842
|
|||
| Drug Name |
111In-hEGF
|
|||
| Synonyms |
Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto
Click to Show/Hide
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Preclinical | [1], [2] | |
| Company |
University of Toronto
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive br... Nucl Med Biol. 2015 Dec;42(12):931-8. | |||
| REF 2 | Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med. 2006 Jun;47(6):1023-31. | |||
| REF 3 | A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000 May;41(5):903-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.